TSHA logo

Taysha Gene Therapies (TSHA)

Profile

Full Name

Taysha Gene Therapies, Inc.

Ticker Symbol

TSHA

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

September 24, 2020

Indexes

Not included

Website

http://www.tayshagtx.com

Employees

73

Key Details

Price

$1.24(+5.08%)

Market cap

$254.20M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$8.33M(-46.07% YoY)

Annual EPS

-$0.36(+62.50% YoY)

PE ratio

-

Next earnings date

May 14, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.24
TSHA price is $1.24

30-Day Relative Volume

0.47
TSHA 30-day relative volume is 0.47

Price Performance

Price Most recent change

+5.08%
TSHA price was up +5.08% on Apr 17, 2025

Price YTD change

-28.32%
TSHA price is down -28.32% since January 1st

Price 1-year change

-49.39%
TSHA price is down -49.39% year-on-year

Price 3-year change

-77.62%
TSHA price is down -77.62% over the past 3 years

Price Range

Price All-time high

$33.35
TSHA price is currently -96.28% below its historical high of $33.35

Price 3-year low

$0.50
TSHA price is currently +148.00% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$254.20M
TSHA market capitalization is $254.20 million

Market cap 3-year change

+19.26%
TSHA market capitalization is up +19.26% over the past 3 years

Market cap All-time high

$1.20B
TSHA market capitalization is currently -78.80% below its historical high of $1.20 billion

Market cap sector rank

60.99%
TSHA market capitalization is higher than 60.99% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+9.62%
TSHA shares outstanding is up +9.62% year-on-year

Shares Outstanding 3-Year Change

+432.83%
TSHA shares outstanding is up +432.83% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.23
TSHA beta is 1.23

200-day SMA

$1.94
TSHA price is currently -35.97% below its 200-day simple moving average

50-day SMA

$1.57
TSHA price is currently -21.07% below its 50-day simple moving average

RSI

40.38
TSHA 14-day relative strength index is 40.38

Volume

0.47
TSHA 30-day relative volume is 0.47

ATR

$0.14
TSHA average true range is $0.14

10-day Historical Volatility

85.59%
TSHA 10-day historical volatility is 85.59%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$8.33M
TSHA annual revenue is $8.33 million

Revenue Analysts estimate

$5.89M
TSHA annual revenue is currently +41.48% higher than the consensus analysts' forecast

Revenue 1-year change

-46.07%
TSHA annual revenue is down -46.07% year-on-year

Revenue Sector rank

25.56%
TSHA annual revenue is higher than 25.56% of companies in Healthcare sector

EPS

EPS

-$0.36
TSHA annual earnings per share is -$0.36

EPS Analysts estimate

-$0.36
TSHA annual earnings per share is currently -1.37% lower than the consensus analysts' forecast

EPS 1-year change

+62.5%
TSHA annual earnings per share is up +62.5% year-on-year

EPS Sector rank

72.25%
TSHA annual earnings per share is higher than 72.25% of companies in Healthcare sector

Profit

Gross profit

-
TSHA annual gross profit value is unknown

Gross margin

-
TSHA annual gross profit margin value is unknown

Operating profit

-$86.62M
TSHA annual operating income is -$86.62 million

Operating margin

-1039.49%
TSHA annual operating profit margin is -1039.49%

Net income

-$89.30M
TSHA annual net profit is -$89.30 million

Net margin

-1071.62%
TSHA annual net profit margin is -1071.62%

Expenses

Total expenses

$94.95M
TSHA annual total expenses is $94.95 million

Operating expenses

$94.95M
TSHA annual total operating expenses is $94.95 million

Cost of goods sold

-
TSHA annual cost of goods sold value is unknown

Selling, general & administrative expenses

$28.95M
TSHA annual SGA is $28.95 million

Depreciation and amortization

$1.25M
TSHA annual depreciation & amortization is $1.25 million

Interest expense

$102.00K
TSHA annual interest expense is $102.00 thousand

Income tax

-
TSHA annual income tax value is unknown

EBIT & EBITDA

EBIT

-$89.20M
TSHA annual earnings before interest & taxes is -$89.20 million

EBITDA

-$87.95M
TSHA annual EBITDA is -$87.95 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$160.36M
TSHA annual total assets is $160.36 million

Non current assets

$18.23M
TSHA annual long term assets is $18.23 million

Current assets

$142.13M
TSHA annual total current assets is $142.13 million

Cash and cash equivalents

$139.04M
TSHA annual cash & cash equivalents is $139.04 million

Accounts receivable

-
TSHA annual accounts receivable value is unknown

Inventory

-
TSHA annual inventory value is unknown

Liabilities

Total liabilities

$88.84M
TSHA annual total liabilities is $88.84 million

Long term liabilities

$62.61M
TSHA annual total long term liabilities is $62.61 million

Current liabilities

$26.23M
TSHA annual total current liabilities is $26.23 million

Accounts payable

$3.59M
TSHA annual accounts payable is $3.59 million

Debt

Total debt

$63.18M
TSHA annual total debt is $63.18 million

Total debt 1-year change

+3.39%
TSHA annual total debt is up +3.39% year-on-year

Long term debt

$61.30M
TSHA annual long term debt is $61.30 million

Short term debt

$1.88M
TSHA annual short term debt is $1.88 million

Equity & Capital

Shareholders equity

$71.53M
TSHA annual stockholders equity is $71.53 million

Book value

$71.53M
TSHA annual book value is $71.53 million

Retained earnings

-$602.30M
TSHA annual retained earnings is -$602.30 million

Working capital

$115.90M
TSHA annual working capital is $115.90 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$81.22M
TSHA annual cash flow from operations is -$81.22 million

Cash from operations 1-year change

-11.24%
TSHA annual cash flow from operations is down -11.24% year-on-year

Cash from investing

-$363.00K
TSHA annual cash flow from investing activities is -$363.00 thousand

Cash from investing 1-year change

+95.06%
TSHA annual cash flow from investing activities is up +95.06% year-on-year

Cash from financing

$76.68M
TSHA annual cash flow from financing activities is $76.68 million

Cash from financing 1-year change

-43.78%
TSHA annual cash flow from financing activities is down -43.78% year-on-year

CAPEX

CAPEX

$374.00K
TSHA annual capital expenditures is $374.00 thousand

CAPEX 1-year change

-94.92%
TSHA annual capital expenditures is down -94.92% year-on-year

Free Cash Flow

Free cash flow

-$81.60M
TSHA annual free cash flow is -$81.60 million

Free cash flow 1-year change

-1.51%
TSHA annual free cash flow is down -1.51% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
TSHA annual gross profit margin value is unknown

Operating margin

-1039.49%
TSHA annual operating profit margin is -1039.49%

Net margin

-1071.62%
TSHA annual net profit margin is -1071.62%

ROA & ROE

ROA

-53.62%
TSHA annual return on assets is -53.62%

ROE

-121.94%
TSHA annual return on equity is -121.94%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
TSHA price to earnings ratio value is unknown

PE ratio Sector rank

-
TSHA price to earnings ratio is unknown

PB Ratio

PB ratio

3.55
TSHA price to book ratio is 3.55

PB ratio Sector rank

76.17%
TSHA price to book ratio is higher than 76.17% of companies in Healthcare sector

PS Ratio

PS ratio

30.51
TSHA price to sales ratio is 30.51

PS ratio Sector rank

89.35%
TSHA price to sales ratio is higher than 89.35% of companies in Healthcare sector

Enterprise value

Enterprise value

$178.35M
TSHA enterprise value is $178.35 million

Enterprise value Sector rank

57.02%
TSHA enterprise value is higher than 57.02% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-2.03
TSHA EV/EBITDA is -2.03

EV/EBITDA Sector rank

31.77%
TSHA EV/EBITDA is higher than 31.77% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

5.42
TSHA annual current ratio is 5.42

Quick ratio

-
TSHA annual quick ratio value is unknown

Leverage

Debt to equity

0.61
TSHA annual debt to equity ratio is 0.61

Interest coverage ratio

-874.47
TSHA annual interest coverage ratio is -874.47

Risk & Stability

Piotroski F-Score

-
TSHA piotroski f-score value is unknown

Altman Z-Score

-4.46
TSHA altman z-score is -4.46

Analyst ratings

Recent major analysts updates

Apr 10, 25 Needham
Buy
Feb 27, 25 Needham
Buy
Feb 26, 25 Chardan Capital
Buy
Jan 6, 25 Needham
Buy
Nov 15, 24 Canaccord Genuity
Buy
Nov 14, 24 Needham
Buy
Nov 14, 24 Chardan Capital
Buy
Nov 14, 24 Cantor Fitzgerald
Overweight
Nov 12, 24 Needham
Buy
Nov 12, 24 JMP Securities
Market Outperform

Institutional Ownership

Similar stocks

MRVI logo
Maravai LifeSciences Holdings (MRVI)
AVIR logo
Atea Pharmaceuticals (AVIR)
XOMA logo
XOMA (XOMA)
VNDA logo
Vanda Pharmaceuticals (VNDA)
EBS logo
Emergent BioSolutions (EBS)
ITOS logo
iTeos Therapeutics (ITOS)
ZIMV logo
ZimVie (ZIMV)
AQST logo
Aquestive Therapeutics (AQST)
HUMA logo
Humacyte (HUMA)
  • What is the ticker symbol for Taysha Gene Therapies?
  • Does Taysha Gene Therapies pay dividends?
  • What sector is Taysha Gene Therapies in?
  • What industry is Taysha Gene Therapies in?
  • What country is Taysha Gene Therapies based in?
  • When did Taysha Gene Therapies go public?
  • Is Taysha Gene Therapies in the S&P 500?
  • Is Taysha Gene Therapies in the NASDAQ 100?
  • Is Taysha Gene Therapies in the Dow Jones?
  • When was Taysha Gene Therapies's last earnings report?
  • When does Taysha Gene Therapies report earnings?
  • Should I buy Taysha Gene Therapies stock now?

What is the ticker symbol for Taysha Gene Therapies?

The ticker symbol for Taysha Gene Therapies is NASDAQ:TSHA

Does Taysha Gene Therapies pay dividends?

No, Taysha Gene Therapies does not pay dividends

What sector is Taysha Gene Therapies in?

Taysha Gene Therapies is in the Healthcare sector

What industry is Taysha Gene Therapies in?

Taysha Gene Therapies is in the Biotechnology industry

What country is Taysha Gene Therapies based in?

Taysha Gene Therapies is headquartered in United States

When did Taysha Gene Therapies go public?

Taysha Gene Therapies's initial public offering (IPO) was on September 24, 2020

Is Taysha Gene Therapies in the S&P 500?

No, Taysha Gene Therapies is not included in the S&P 500 index

Is Taysha Gene Therapies in the NASDAQ 100?

No, Taysha Gene Therapies is not included in the NASDAQ 100 index

Is Taysha Gene Therapies in the Dow Jones?

No, Taysha Gene Therapies is not included in the Dow Jones index

When was Taysha Gene Therapies's last earnings report?

Taysha Gene Therapies's most recent earnings report was on Feb 26, 2025

When does Taysha Gene Therapies report earnings?

The next expected earnings date for Taysha Gene Therapies is May 14, 2025

Should I buy Taysha Gene Therapies stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page